Roberto Alvarez-Lafuente

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3895302/publications.pdf

Version: 2024-02-01

86 papers	2,432 citations	201674 27 h-index	233421 45 g-index
90 all docs	90 docs citations	90 times ranked	3102 citing authors

#	Article	IF	Citations
1	Classification of HHV-6A and HHV-6B as distinct viruses. Archives of Virology, 2014, 159, 863-870.	2.1	292
2	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
3	Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection. Archives of Neurology, 2004, 61, 1523.	4.5	102
4	Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e321.	6.0	89
5	Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Annals of the Rheumatic Diseases, 2005, 64, 780-782.	0.9	75
6	Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum. Journal of Clinical Microbiology, 2008, 46, 2700-2706.	3.9	73
7	Active Human Herpesvirus 6 Infection in Patients With Multiple Sclerosis. Archives of Neurology, 2002, 59, 929.	4.5	69
8	Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 595-601.	3.0	67
9	Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. Annals of the Rheumatic Diseases, 2005, 64, 1357-1359.	0.9	66
10	Human Herpesvirus 6 and Multiple Sclerosis: A One-Year Follow-up Study. Brain Pathology, 2006, 16, 20-27.	4.1	65
11	The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. PLoS ONE, 2013, 8, e53623.	2.5	64
12	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
13	Immunoglobulin <scp>M</scp> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. Annals of Neurology, 2014, 76, 231-240.	5.3	51
14	Clinical parameters and HHV-6 active replication in relapsingâ€”remitting multiple sclerosis patients. Journal of Clinical Virology, 2006, 37, S24-S26.	3.1	48
15	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
16	Detection of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus in formalin-fixed tissues from sudden infant death: A study with quantitative real-time PCR. Forensic Science International, 2008, 178, 106-111.	2.2	39
17	Large-scale gene expression in bone marrow mesenchymal stem cells: a putative role for COL10A1 in osteoarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1880-1885.	0.9	38
18	Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes and Immunity, 2011, 12, 40-45.	4.1	36

#	Article	IF	Citations
19	Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. PLoS ONE, 2014, 9, e104836.	2.5	36
20	Syncytinâ€1/HERVâ€W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. European Journal of Immunology, 2020, 50, 685-694.	2.9	35
21	Virological analysis in the diagnosis of sudden children death: A medico-legal approach. Forensic Science International, 2006, 161, 8-14.	2.2	33
22	JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Multiple Sclerosis Journal, 2007, 13, 590-595.	3.0	30
23	Environmentâ€“gene interaction in multiple sclerosis: Human herpesvirus 6 and MHC2TA. Human Immunology, 2007, 68, 685-689.	2.4	30
24	Human parvovirus B19, varicella zoster virus, and human herpesvirus-6 in mesenchymal stem cells of patients with osteoarthritis: analysis with quantitative real-time polymerase chain reaction. Osteoarthritis and Cartilage, 2007, 15, 475-478.	1.3	30
25	HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV. Retrovirology, 2014, 11, 2.	2.0	30
26	Prevalence of herpesvirus DNA in MS patients and healthy blood donors. Acta Neurologica Scandinavica, 2002, 105, 95-99.	2.1	29
27	MHC2TA rs4774C and HHVâ€6A active replication in multiple sclerosis patients. European Journal of Neurology, 2010, 17, 129-135.	3.3	29
28	Human Endogenous Retrovirus HERV-Fc1 Association with Multiple Sclerosis Susceptibility: A Meta-Analysis. PLoS ONE, 2014, 9, e90182.	2.5	29
29	Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressive. Multiple Sclerosis Journal, 2007, 13, 578-583.	3.0	28
30	Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. European Journal of Neurology, 2011, 18, 1027-1035.	3.3	27
31	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 741-752.	3.0	26
32	Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the â€˜hygiene hypothesisâ€™?. European Journal of Neurology, 2018, 25, 925-933.	3.3	26
33	Role of the Human Endogenous Retrovirus HERV-K18 in Autoimmune Disease Susceptibility: Study in the Spanish Population and Meta-Analysis. PLoS ONE, 2013, 8, e62090.	2.5	25
34	Identification of the major <scp>HHV</scp>â€6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis. European Journal of Neurology, 2014, 21, 1096-1101.	3.3	25
35	Beta-Interferon Treatment Reduces Human Herpesvirus-6 Viral Load in Multiple Sclerosis Relapses but Not in Remission. European Neurology, 2004, 52, 87-91.	1.4	24
36	Acetate correlates with disability and immune response in multiple sclerosis. PeerJ, 2020, 8, e10220.	2.0	23

#	Article	IF	Citations
37	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Annals of Clinical and Translational Neurology, 2019, 6, 355-363.	3.7	21
38	CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Multiple Sclerosis Journal, 2011, 17, 513-520.	3.0	19
39	Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab. Journal of NeuroImmune Pharmacology, 2013, 8, 1277-1286.	4.1	19
40	Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. Cytokine, 2013, 61, 720-723.	3.2	19
41	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-Î² therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	3.2	19
42	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	6.0	19
43	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	2.3	18
44	Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e62540.	2.5	18
45	Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. Journal of Neuroimmunology, 2017, 306, 40-45.	2.3	17
46	Adaptive Features of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 2403.	4.8	17
47	Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. European Journal of Neurology, 2019, 26, 1200-1204.	3.3	17
48	Study of the possible link of 25â€hydroxyvitamin D with Epsteinâ€“Barr virus and human herpesvirus 6 in patients with multiple sclerosis. European Journal of Neurology, 2018, 25, 1446-1453.	3.3	16
49	TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis. PLoS ONE, 2011, 6, e21766.	2.5	16
50	Herpesvirus active replication in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 98-102.	0.6	15
51	Neutralizing antibodies, MxA expression and MMPâ€9/TIMPâ€1 ratio as markers of bioavailability of interferonâ€beta treatment in multiple sclerosis patients: a twoâ€year followâ€up study. European Journal of Neurology, 2010, 17, 470-478.	3.3	14
52	Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition. Genes and Immunity, 2011, 12, 145-148.	4.1	14
53	MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. BMC Neurology, 2012, 12, 107.	1.8	14
54	Study of the antiâ€<scp>JCV</scp> antibody levels in a Spanish multiple sclerosis cohort. European Journal of Clinical Investigation, 2017, 47, 158-166.	3.4	14

#	Article	IF	Citations
55	Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. European Journal of Neurology, 2007, 14, 233-236.	3.3	13
56	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	4.8	13
57	Real-time polymerase chain reaction detection of Neisseria meningitidis in formalin-fixed tissues from sudden deaths. Diagnostic Microbiology and Infectious Disease, 2008, 60, 339-346.	1.8	12
58	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Scientific Reports, 2020, 10, 14244.	3.3	12
59	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells, 2021, 10, 119.	4.1	12
60	Tollâ€like receptorâ€9 in <scp>S</scp>panish multiple sclerosis patients: an association with the gender. European Journal of Neurology, 2014, 21, 537-540.	3.3	11
61	Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. European Journal of Neurology, 2016, 23, 182-189.	3.3	11
62	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology, 2018, 265, 24-31.	3.6	11
63	CD46 expression and HHV-6 infection in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2009, 120, 246-250.	2.1	10
64	Serum antibodies to phosphatidylcholine in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e765.	6.0	10
65	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	2.4	9
66	Significance of nested PCR and quantitative real time PCR for cytomegalovirus detection in renal transplant recipients. International Journal of Antimicrobial Agents, 2004, 24, 455-462.	2.5	8
67	Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients. Journal of NeuroVirology, 2007, 13, 504-512.	2.1	8
68	The ubiquitinâ€“proteasome pathway and viral infections in articular cartilage of patients with osteoarthritis. Rheumatology International, 2009, 29, 969-972.	3.0	8
69	Expression of human endogenous retrovirus HERV-K18 is associated with clinical severity in osteoarthritis patients. Scandinavian Journal of Rheumatology, 2013, 42, 498-504.	1.1	8
70	MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Frontiers in Immunology, 2020, 11, 2142.	4.8	7
71	Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis. Journal of the Neurological Sciences, 2020, 414, 116811.	0.6	7
72	Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. Biomedicines, 2022, 10, 387.	3.2	7

#	Article	IF	Citations
73	Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid. Clinical Neuropharmacology, 2017, 40, 29-33.	0.7	6
74	JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab. Scandinavian Journal of Rheumatology, 2016, 45, 507-511.	1.1	5
75	Shortâ€chain fatty acids during pregnancy in multiple sclerosis: A prospective cohort study. European Journal of Neurology, 2022, 29, 895-900.	3.3	5
76	Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment. Frontiers in Immunology, 2021, 12, 778204.	4.8	5
77	Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion. BBA Clinical, 2015, 3, 162-167.	4.1	4
78	A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 771.	4.8	4
79	Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain. PeerJ, 2019, 7, e8235.	2.0	4
80	New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis. Current Medicinal Chemistry, 2018, 25, 3272-3283.	2.4	3
81	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology, 2021, 12, 760546.	4.8	3
82	Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. Frontiers in Immunology, 2021, 12, 798003.	4.8	3
83	High prevalence of intrathecal IgA synthesis in multiple sclerosis patients. Scientific Reports, 2022, 12, 4247.	3.3	1
84	Evolution of antibody titres against Epsteinâ€“Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients. Scientific Reports, 2021, 11, 8441.	3.3	0
85	Serum IgM to Lipids Predicts the Response to TysabriÂ® and IFN-Î² in MS. SSRN Electronic Journal, 0, , .	0.4	0
86	Clinical Data Associated With the Therapeutic Response to Glatiramer Acetate in Multiple Sclerosis Patients. Neuro - Open Journal, 2016, 3, 3-8.	0.1	0